跳到正文
原文
STAT Pharma 医药频道· Jason Mast·· 17 天前AI 评分40

Servier 的 $1.55 亿美元肌营养不良药物在关键 III 期试验中失败

STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test

AI 导读

法国制药公司 Servier 的肌营养不良药物 sevasemten 在 III 期试验中未能减缓贝克尔型肌营养不良的症状,此前该药物在较小的随机研究中表现出积极结果。Servier 正在全面分析试验数据以进一步理解研究结果。目前贝克尔型肌营养不良患者尚无获批治疗药物。

正文

By Jason Mast

Nov. 3, 2026

General Assignment Reporter

The French pharma Servier said Tuesday that an experimental drug it purchased in June for $1.55 billion in cash, plus about $1 billion more in potential milestones, failed to slow a rare form of muscular dystrophy in a long placebo-controlled trial.

It’s a surprising setback for both Servier and for patients with Becker muscular dystrophy, who currently have no approved treatments. The drug, called sevasemten and originally developed by Edgewise Therapeutics, had previously shown promising results in a smaller, randomized study.

“The results of the pivotal GRAND CANYON study are not aligned with certain findings observed in prior clinical studies,” Servier said in a statement, using the company’s name for the Phase 3 trial. “Servier is conducting a comprehensive analysis of the GRAND CANYON study dataset, together with relevant prior clinical data, to better understand and further characterize the study findings.”

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com